Bicycle Therapeutics plc

NasdaqGS:BCYC Stock Report

Mkt Cap: US$831.3m

Bicycle Therapeutics Future Growth

How is Bicycle Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


3.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

NasdaqGS:BCYC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202546-200-176-12710
12/31/202418-176-156-12112
12/31/202316-138-127-9714
9/30/202215-101-85-66N/A
6/30/202216-87-54-39N/A
3/31/202214-78-34-27N/A
12/31/202112-67-17-15N/A
9/30/202112-66-22-21N/A
6/30/202111-62-54-53N/A
3/31/202111-56-54-53N/A
12/31/202010-51-19-18N/A
9/30/202012-38-7-6N/A
6/30/20209-37-8-7N/A
3/31/20209-35-4-2N/A
12/31/201914-31-30-29N/A
9/30/201910-33-34-33N/A
6/30/201911-31-28-26N/A
3/31/201911-26-25-24N/A
12/31/20187-22-27-26N/A
9/30/20187-21-20-19N/A
12/31/20172-16-3-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCYC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCYC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCYC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BCYC's revenue (61.6% per year) is forecast to grow faster than the US market (7% per year).

High Growth Revenue: BCYC's revenue (61.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BCYC is forecast to be unprofitable in 3 years.


Discover growth companies